Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Type 1 Diabetes (Juvenile Diabetes)-Pipeline Review, H1 2015

Type 1 Diabetes (Juvenile Diabetes)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Type 1 Diabetes (Juvenile Diabetes)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Type 1 Diabetes (Juvenile Diabetes)-Pipeline Review, H1 2015', provides an overview of the Type 1 Diabetes (Juvenile Diabetes)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Type 1 Diabetes (Juvenile Diabetes) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Type 1 Diabetes (Juvenile Diabetes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Type 1 Diabetes (Juvenile Diabetes) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Type 1 Diabetes (Juvenile Diabetes) Overview 8

Therapeutics Development 9

Type 1 Diabetes (Juvenile Diabetes)-Therapeutics under Development by Companies 11

Type 1 Diabetes (Juvenile Diabetes)-Therapeutics under Investigation by Universities/Institutes 21

Type 1 Diabetes (Juvenile Diabetes)-Pipeline Products Glance 24

Type 1 Diabetes (Juvenile Diabetes)-Products under Development by Companies 27

Type 1 Diabetes (Juvenile Diabetes)-Products under Investigation by Universities/Institutes 39

Type 1 Diabetes (Juvenile Diabetes)-Companies Involved in Therapeutics Development 41

Type 1 Diabetes (Juvenile Diabetes)-Therapeutics Assessment 134

Drug Profiles 146

Type 1 Diabetes (Juvenile Diabetes)-Recent Pipeline Updates 407

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects 511

Type 1 Diabetes (Juvenile Diabetes)-Discontinued Products 519

Appendix 521

List of Tables

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2015 30

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes)-Comparative Analysis, H1 2015 31

Number of Products under Development by Companies, H1 2015 33

Number of Products under Development by Companies, H1 2015 (Contd..1) 34

Number of Products under Development by Companies, H1 2015 (Contd..2) 35

Number of Products under Development by Companies, H1 2015 (Contd..3) 36

Number of Products under Development by Companies, H1 2015 (Contd..4) 37

Number of Products under Development by Companies, H1 2015 (Contd..5) 38

Number of Products under Development by Companies, H1 2015 (Contd..6) 39

Number of Products under Development by Companies, H1 2015 (Contd..7) 40

Number of Products under Development by Companies, H1 2015 (Contd..8) 41

Number of Products under Investigation by Universities/Institutes, H1 2015 43

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 44

Comparative Analysis by Late Stage Development, H1 2015 45

Comparative Analysis by Clinical Stage Development, H1 2015 46

Comparative Analysis by Early Stage Development, H1 2015 47

Products under Development by Companies, H1 2015 48

Products under Development by Companies, H1 2015 (Contd..1) 49

Products under Development by Companies, H1 2015 (Contd..2) 50

Products under Development by Companies, H1 2015 (Contd..3) 51

Products under Development by Companies, H1 2015 (Contd..4) 52

Products under Development by Companies, H1 2015 (Contd..5) 53

Products under Development by Companies, H1 2015 (Contd..6) 54

Products under Development by Companies, H1 2015 (Contd..7) 55

Products under Development by Companies, H1 2015 (Contd..8) 56

Products under Development by Companies, H1 2015 (Contd..9) 57

Products under Development by Companies, H1 2015 (Contd..10) 58

Products under Development by Companies, H1 2015 (Contd..11) 59

Products under Investigation by Universities/Institutes, H1 2015 60

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 61

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by 4SC AG, H1 2015 62

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by ActogeniX NV, H1 2015 63

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Adocia, H1 2015 64

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by AiCuris GmbH & Co. KG, H1 2015 65

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 66

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Ambrx, Inc., H1 2015 67

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by American Gene Technologies International Inc., H1 2015 68

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by AntriaBio, Inc., H1 2015 69

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Argos Therapeutics, Inc., H1 2015 70

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Artery Therapeutics, Inc., H1 2015 71

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by AstraZeneca PLC, H1 2015 72

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Axxam SpA, H1 2015 73

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Bayhill Therapeutics, Inc., H1 2015 74

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Beta-Cell NV, H1 2015 75

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Biocon Limited, H1 2015 76

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Biodel Inc., H1 2015 77

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Biogenomics Limited, H1 2015 78

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by BioLineRx, Ltd., H1 2015 79

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by BioTherapeutics Inc., H1 2015 80

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Boehringer Ingelheim GmbH, H1 2015 81

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Carlina Technologies SAS, H1 2015 82

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Cellectis S.A., H1 2015 83

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Compugen Ltd., H1 2015 84

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Cortendo AB, H1 2015 85

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by CTI BioPharma Corp., H1 2015 86

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 87

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Diabetology Limited, H1 2015 88

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by DiaMedica Inc., H1 2015 89

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Diasome Pharmaceuticals, Inc., H1 2015 90

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Dompe Farmaceutici S.p.A., H1 2015 91

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by DoNatur GmbH, H1 2015 92

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Effimune SAS, H1 2015 93

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Eli Lilly and Company, H1 2015 94

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by EpiVax, Inc., H1 2015 95

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Evotec AG, H1 2015 96

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Extrawell Pharmaceutical Holdings Limited, H1 2015 97

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by GeNeuro SA, H1 2015 98

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Gilead Sciences, Inc., H1 2015 99

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by GlaxoSmithKline plc, H1 2015 100

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Grifols, S.A., H1 2015 101

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Halozyme Therapeutics, Inc., H1 2015 102

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 103

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Hyperion Therapeutics, Inc., H1 2015 104

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Iltoo Pharma, H1 2015 105

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Immunocore Limited, H1 2015 106

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Intrexon Corporation, H1 2015 107

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Islet Sciences, Inc., H1 2015 108

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Johnson & Johnson, H1 2015 109

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Kamada Ltd., H1 2015 110

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Kasiak Research Pvt. Ltd., H1 2015 111

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Kineta, Inc., H1 2015 112

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 113

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Lexicon Pharmaceuticals, Inc., H1 2015 114

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 115

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by MacroGenics, Inc., H1 2015 116

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Medestea Research & Production S.p.A., H1 2015 117

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by MedImmune, LLC, H1 2015 118

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Merck & Co., Inc., H1 2015 119

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Merck KGaA, H1 2015 120

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Meridigen Biotech Co., Ltd., H1 2015 121

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Mertiva AB, H1 2015 122

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by MidaSol Therapeutics LP, H1 2015 123

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 124

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by NeoStem, Inc., H1 2015 125

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by NGM Biopharmaceuticals, Inc., H1 2015 126

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Novo Nordisk A/S, H1 2015 127

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Noxxon Pharma AG, H1 2015 128

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Omni Bio Pharmaceutical Inc., H1 2015 129

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Opexa Therapeutics, Inc., H1 2015 130

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Oramed Pharmaceuticals, Inc., H1 2015 131

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Orgenesis, Inc., H1 2015 132

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2015 133

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Pfizer Inc., H1 2015 134

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by PharmaCyte Biotech, Inc., H1 2015 135

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by PharmaIN Corporation, H1 2015 136

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Progen Pharmaceuticals Limited, H1 2015 137

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Prometheon Pharma, LLC, H1 2015 138

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Provid Pharmaceuticals, Inc., H1 2015 139

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by RedHill Biopharma Ltd., H1 2015 140

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by REGiMMUNE Corporation, H1 2015 141

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Sanofi, H1 2015 142

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by SEKRIS Biomedical, Inc., H1 2015 143

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Selecta Biosciences, Inc., H1 2015 144

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Shreya Life Sciences Pvt. Ltd., H1 2015 145

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Therapix Biosciences Ltd, H1 2015 146

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Thermalin Diabetes, LLC, H1 2015 147

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Toleranzia AB, H1 2015 148

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Transgene Biotek Limited, H1 2015 149

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Uni-Bio Science Group Ltd., H1 2015 150

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by ViaCyte, Inc., H1 2015 151

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by Visionary Pharmaceuticals, Inc., H1 2015 152

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by X-BODY BioSciences, Inc., H1 2015 153

Type 1 Diabetes (Juvenile Diabetes)-Pipeline by XOMA Corporation, H1 2015 154

Assessment by Monotherapy Products, H1 2015 155

Assessment by Combination Products, H1 2015 156

Number of Products by Stage and Target, H1 2015 158

Number of Products by Stage and Mechanism of Action, H1 2015 161

Number of Products by Stage and Route of Administration, H1 2015 164

Number of Products by Stage and Molecule Type, H1 2015 166

Type 1 Diabetes (Juvenile Diabetes) Therapeutics-Recent Pipeline Updates, H1 2015 428

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects, H1 2015 532

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects (Contd..1), H1 2015 533

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects (Contd..2), H1 2015 534

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects (Contd..3), H1 2015 535

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects (Contd..4), H1 2015 536

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects (Contd..5), H1 2015 537

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects (Contd..6), H1 2015 538

Type 1 Diabetes (Juvenile Diabetes)-Dormant Projects (Contd..7), H1 2015 539

Type 1 Diabetes (Juvenile Diabetes)-Discontinued Products, H1 2015 540

Type 1 Diabetes (Juvenile Diabetes)-Discontinued Products (Contd..1), H1 2015 541

List of Figures

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2015 30

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes)-Comparative Analysis, H1 2015 31

Number of Products under Development by Companies, H1 2015 32

Number of Products under Investigation by Universities/Institutes, H1 2015 42

Comparative Analysis by Late Stage Development, H1 2015 45

Comparative Analysis by Clinical Stage Development, H1 2015 46

Comparative Analysis by Early Stage Products, H1 2015 47

Assessment by Monotherapy Products, H1 2015 155

Assessment by Combination Products, H1 2015 156

Number of Products by Top 10 Targets, H1 2015 157

Number of Products by Stage and Top 10 Targets, H1 2015 157

Number of Products by Top 10 Mechanism of Actions, H1 2015 160

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 160

Number of Products by Top 10 Routes of Administration, H1 2015 163

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 164

Number of Products by Top 10 Molecule Types, H1 2015 165

Number of Products by Stage and Top 10 Molecule Types, H1 2015 166

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

ActogeniX NV

Adocia

AiCuris GmbH & Co. KG

Amarantus Bioscience Holdings, Inc.

Ambrx, Inc.

American Gene Technologies International Inc.

AntriaBio, Inc.

Argos Therapeutics, Inc.

Artery Therapeutics, Inc.

AstraZeneca PLC

Axxam SpA

Bayhill Therapeutics, Inc.

Beta-Cell NV

Biocon Limited

Biodel Inc.

Biogenomics Limited

BioLineRx, Ltd.

BioTherapeutics Inc.

Boehringer Ingelheim GmbH

Carlina Technologies SAS

Cellectis S.A.

Compugen Ltd.

Cortendo AB

CTI BioPharma Corp.

Daewoong Pharmaceutical Co., Ltd.

Diabetology Limited

DiaMedica Inc.

Diasome Pharmaceuticals, Inc.

Dompe Farmaceutici S.p.A.

DoNatur GmbH

Effimune SAS

Eli Lilly and Company

EpiVax, Inc.

Evotec AG

Extrawell Pharmaceutical Holdings Limited

GeNeuro SA

Gilead Sciences, Inc.

GlaxoSmithKline plc

Grifols, S.A.

Halozyme Therapeutics, Inc.

Hanmi Pharmaceuticals, Co. Ltd.

Hyperion Therapeutics, Inc.

Iltoo Pharma

Immunocore Limited

Intrexon Corporation

Islet Sciences, Inc.

Johnson & Johnson

Kamada Ltd.

Kasiak Research Pvt. Ltd.

Kineta, Inc.

Kissei Pharmaceutical Co., Ltd.

Lexicon Pharmaceuticals, Inc.

Ligand Pharmaceuticals, Inc.

MacroGenics, Inc.

Medestea Research & Production S.p.A.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Meridigen Biotech Co., Ltd.

Mertiva AB

MidaSol Therapeutics LP

Mitsubishi Tanabe Pharma Corporation

NeoStem, Inc.

NGM Biopharmaceuticals, Inc.

Novo Nordisk A/S

Noxxon Pharma AG

Omni Bio Pharmaceutical Inc.

Opexa Therapeutics, Inc.

Oramed Pharmaceuticals, Inc.

Orgenesis, Inc.

Paras Biopharmaceuticals Finland Oy

Pfizer Inc.

PharmaCyte Biotech, Inc.

PharmaIN Corporation

Progen Pharmaceuticals Limited

Prometheon Pharma, LLC

Provid Pharmaceuticals, Inc.

RedHill Biopharma Ltd.

REGiMMUNE Corporation

Sanofi

SEKRIS Biomedical, Inc.

Selecta Biosciences, Inc.

Shreya Life Sciences Pvt. Ltd.

Therapix Biosciences Ltd

Thermalin Diabetes, LLC

Toleranzia AB

Transgene Biotek Limited

Uni-Bio Science Group Ltd.

ViaCyte, Inc.

Visionary Pharmaceuticals, Inc.

X-BODY BioSciences, Inc.

XOMA Corporation

Type 1 Diabetes (Juvenile Diabetes) Therapeutic Products under Development, Key Players in Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Type 1 Diabetes (Juvenile Diabetes) Pipeline Overview, Type 1 Diabetes (Juvenile Diabetes) Pipeline, Type 1 Diabetes (Juvenile Diabetes) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com